Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 2024 Jefferies London Healthcare Conference November 19, 2024 6:00 AM ET
Company Participants
Ryan Crowe – SVP, IR and Strategic Analysis
Marion McCourt – EVP, Commercial
Conference Call Participants
Akash Tewari – Jefferies
Akash Tewari
Good morning, everyone. Thanks so much for joining us. Day one of our healthcare conference. My name is Akash Tewari. I’m a pharma and biotech analyst here at Jefferies. This is the Regeneron management team. We have Ryan, Head of IR; and then Marion McCourt, Executive Vice President. Always a pleasure to have them in this conference.
Ryan, why don’t I hand it off to you for some intro remarks, and then we’ll get started.
Ryan Crowe
Thanks, Akash. Great conference, as usual, very great meeting so far. And I’m just going to read this forward-looking statement, and we’ll get started with your questions. I’d like to remind you that remarks made today may include forward-looking statements about Regeneron. And each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements.
The description of material risks and uncertainties can be found in Regeneron’s SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Back to you, Akash.
Question-and-Answer Session
Q – Akash Tewari
All right. So look, I wanted to start off maybe with high-dose EYLEA because I think that’s where we get the most amount of questions, and this is what I tell investors a lot. Everyone’s like, “Oh, my god, the high-dose EYLEA launch is disappointing.” And I point out to investors if you peg the launch of high-dose EYLEA versus low-dose EYLEA and VABYSMO, it is still the best launch we’ve seen in wet AMD in history thus far.
Read the full article here